Slides
Page 1
1Q Fiscal 2026 Webcast February 19, 2026
Page 2
Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company’s ability to successfully integrate acquisitions; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including new or increased tariffs or trade restrictions; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, conflicts or wars between sovereign nations, acts of terror, natural disasters and pandemics, and the other factors discussed in Item 1A (Risk Factors) in the Company’s most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this presentation. 2 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Page 3
Agenda ▪ 1st Quarter Highlights ▪ Sales & Earnings Performance ▪ Balance Sheet and Cash Flow 1Q 2026 Webcast – February 19, 2026 3 ▪ Enterprise Performance ▪ 2026 Guidance Update ▪ Q&A Dan Hopgood Executive Vice President & Chief Financial Officer Sundaram Nagarajan President & Chief Executive Officer Lara Mahoney Vice President, Investor Relations
Page 4
Strong operating performance, adjusted EPS above the midpoint of 1Q 26 guidance 1Q 2026 Highlights Record 1Q sales of $669M, a 9% increase over prior year, including 7% organic growth Organic growth in all segments, as end markets continue to inflect and stabilize Record 1Q EBITDA of $203M, or 30% of sales Record 1Q adjusted EPS of $2.37, a 15% increase over prior year Continued strong cash flow performance 4
Page 5
1Q 2025 1Q 2026 ∆ Sales $615.4 $669.5 9% Adj. Operating Profit* $151.1 $166.4 10% EBITDA* $188.1 $203.0 8% EPS GAAP $1.65 $2.38 44% EPS Adjusted* $2.06 $2.37 15% *Non-GAAP numbers - See appendix for reconciliation. In millions except for per share data. Total Company – 1Q 2026 5 Sales ▪ Reported sales of $669M, an increase of 9% compared to the prior year, inclusive of previously divested medical contract manufacturing business ▪ 7% organic sales increase driven by growth in all segments ▪ Favorable currency impact of 4% and unfavorable net impact of 1% from divested sales EBITDA ▪ EBITDA was $203 million, up 8% over prior year ▪ Strong EBITDA margin of 30%, in line with prior year **Amounts may not add due to rounding. $615 $40 $(9) $23 $669 1Q 2025 Organic Acq/Div Currency 1Q 2026 1Q 2026 Sales Bridge**
Page 6
Industrial Precision Solutions – 1Q 2026 6 Sales ▪ Sales of $327 million, a 9% increase ▪ Organic sales increased 3% compared to 1Q 2025 driven by growth across most product lines with particular strength in Asia Pacific markets ▪ Favorable currency impact of 6% EBITDA ▪ EBITDA was $110 million, or 34% of sales, down 2% over prior year related to product and geographic mix 37% 37% 38% $300 $10 $17 $327 1Q 2025 Organic Currency 1Q 2026 1Q 2026 IPS Sales Bridge* $126 $113 $110 37% 38% 34% 1Q 2024 1Q 2025 1Q 2026 EBITDA and Margin *Amounts may not add due to rounding.
Page 7
Medical and Fluid Solutions – 1Q 2026 7 Sales ▪ Sales of $193 million, relatively flat compared to prior year inclusive of the divested sales impact of (4)% ▪ Organic sales increase of 3% from growth in engineered fluid solutions product lines EBITDA ▪ EBITDA was $70 million, or 36% of sales, an increase of 9% compared to the prior year ▪ EBITDA margin improvement was driven by the divestiture, organic sales volume, and strong incremental performance $(8) $3 $194 $5 $193 1Q 2025 Organic Divestiture Currency 1Q 2026 1Q 2026 MFS Sales Bridge* $60 $64 $70 37% 33% 36% 1Q 2024 1Q 2025 1Q 2026 EBITDA and Margin *Amounts may not add due to rounding.
Page 8
Advanced Technology Solutions – 1Q 2026 8 Sales ▪ Sales were $149 million, an increase of 23% ▪ 21% organic sales increase driven by ongoing strength in electronics dispense systems and recovering demand for x-ray systems ▪ Favorable currency impact of 2% EBITDA ▪ EBITDA was $33 million, or 22% of sales, an increase of 43% compared to the prior year ▪ EBITDA margin improvement compared to prior year reflects stronger sales volume and related leverage $121 $25 $3 $149 1Q 2025 Organic Currency 1Q 2026 $23 $23 $33 17% 19% 22% 1Q 2024 1Q 2025 1Q 2026 EBITDA and Margin *Amounts may not add due to rounding. 1Q 2026 ATS Sales Bridge*
Page 9
Balance Sheet and Cash Flow 9 109% 33% 33% *Non-GAAP number – See appendix for reconciliation. $2,089 $1,888 $1,877 2.5x 2.1x 2.1x 2024 2025 1Q 2026 Net Debt Leverage Ratio $165 $138 $123 150% 146% 105% 1Q 2024 1Q 2025 1Q 2026 Free Cash Flow Conversion % Balanced Capital Deployment Returning Value to Shareholders Free Cash Flow* ▪ Free cash flow of $123 million, which is a conversion rate of 105% excluding the non-cash gain (third consecutive quarter above 100%) Net Debt ▪ Cash totaled $120 million ▪ 2.1x net debt leverage ratio based on trailing 12-month EBITDA, consistent with year end results
Page 10
Strategic Capital Allocation Invested $18M in capital investments to fuel new capabilities and future growth Paid $46M in dividends Completed $82M in share repurchases Entered a $1.2B new credit agreement ▪ Term debt converted with no change in total debt outstanding ▪ Increased flexibility to pursue strategic opportunities 10
Page 11
11 End Market Visibility Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions ▪ Global production shifts in manufacturing ▪ Long-term growth drivers remain attractive ▪ Investments in dispense and surface treatment product lines, while x-ray systems are starting to inflect ▪ General and automotive electronics stable ▪ Sustaining investments in packaging and product assembly end markets ▪ Continued growth in precision agriculture in Europe and South America ▪ Polymer processing and automotive end markets have stabilized ▪ Stable aftermarket demand ▪ Supply chain normalized in interventional product lines, returning to market growth ▪ Healthy pipeline of customer projects ▪ Electronics and industrial investments are driving growth in engineered fluid solutions product lines
Page 12
Why Nordson Wins in Advanced Electronics 12 The Nordson Vantage system enhances automation, precision, and dispense accuracy for advanced packaging, coupled with quality controls including closed-loop process control, predictive maintenance and real-time process insights. ▪ Broad and market leading technology portfolio ▪ Market-leading Nordson® Vantage ® and Spectrum® S2 systems enable underfill and encapsulation which allow the stacking of increasingly small chips ▪ Nordson optical, acoustic and x-ray inspection technologies inspect increasingly higher density of miniature connections ▪ Leaders in application knowledge with close to the customer business model ▪ Technologically and geographically well positioned as investments expand in other regions ▪ NBS Next growth framework ensures crystal clear focus on best opportunities
Page 13
$651 $683 2Q 2024 2Q 2025 2Q 2026 2Q FY2026 Revenue Guidance 2Q Fiscal 2026 Guidance 13 Momentum in electronic end markets while industrial and medical end markets experience stable demand ▪ 2Q FY2026 revenue of $710 - $740 million ▪ 2Q FY2026 adjusted earnings per share in the range of $2.70 - $2.90 ▪ Context: healthy backlog entering the quarter and strong order entry trends; assumes FX rates remain at current levels $710 - $740 $2.34 $2.42 2Q 2024 2Q 2025 2Q 2026 2Q FY2026 Adjusted EPS Guidance $2.70 - $2.90
Page 14
14 2026 Fiscal Full Year Guidance Guidance Metric Initial Guidance Updated Guidance Reported Sales $2,830 - $2,950 $2,860 - $2,980 Adjusted EPS $10.80 - $11.50 $11.00 - $11.60 ▪ Assumes FX rates hold at current levels and other assumptions remain unchanged ▪ Adjusted earnings now expected to grow 7% – 13%, up 10% YOY at the midpoint ▪ Backlog grew approximately 4% YOY and order entry trends encouraging ▪ Fiscal 2026 sales growth now expected in the range of ~3% to 7% YOY Increasing Our Full Year Outlook after Strong 1Q Result
Page 15
Questions?
Page 16
16 Reconciliation of Non-GAAP Measures Net Income to EBITDA (Dollars in thousands)
Page 17
17 Reconciliation of Non-GAAP Measures Adjusted Net Income and Earnings Per Share (Dollars in thousands)
Page 18
18 Reconciliation of Non-GAAP Measures Operating Cash Flow to Free Cash Flow